Medical management of neurofibromatosis

International Journal of DermatologyEarly View Letter to the Editor Medical management of neurofibromatosis Meet Kachhadia, Meet Kachhadia Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Rajkot, Gujarat, IndiaSearch for more papers by this authorYashdeep Singh Pathania, Corresponding Author Yashdeep Singh Pathania [email protected] orcid.org/0000-0003-3462-1625 Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Rajkot, Gujarat, IndiaSearch for more papers by this author Meet Kachhadia, Meet Kachhadia Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Rajkot, Gujarat, IndiaSearch for more papers by this authorYashdeep Singh Pathania, Corresponding Author Yashdeep Singh Pathania [email protected] orcid.org/0000-0003-3462-1625 Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Rajkot, Gujarat, IndiaSearch for more papers by this author First published: 09 August 2024 https://doi.org/10.1111/ijd.17430 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro-Oncology. 2015; 17(4): 596–603. https://doi.org/10.1093/neuonc/nou235. Erratum in: Neuro Oncol. 2015 Jun;17(6):905. 10.1093/neuonc/nou235 CASPubMedWeb of Science®Google Scholar 2Jakacki RI, Dombi E, Steinberg SM, Goldman S, Kieran MW, Ullrich NJ, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro-Oncology. 2017; 19(2): 289–297. https://doi.org/10.1093/neuonc/now158 10.1093/neuonc/now158 CASPubMedGoogle Scholar 3Gross AM, Dombi E, Wolters PL, Baldwin A, Dufek A, Herrera K, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology. 2023; 25(10): 1883–1894. https://doi.org/10.1093/neuonc/noad086 10.1093/neuonc/noad086 CASPubMedGoogle Scholar 4Hwang J, Yoon HM, Lee BH, Kim PH, Kim KW. Efficacy and safety of selumetinib in pediatric patients with neurofibromatosis type 1: a systematic review and meta-analysis. Neurology. 2022; 98(9): e938–e946. https://doi.org/10.1212/WNL.0000000000013296 10.1212/WNL.0000000000013296 CASPubMedGoogle Scholar 5Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P, et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020; 15(1): 37. https://doi.org/10.1186/s13023-020-1310-3 10.1186/s13023-020-1310-3 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation